Advertisement

Risk factors for acne development in the first 2 years after initiating masculinizing testosterone therapy among transgender men

Published:January 31, 2019DOI:https://doi.org/10.1016/j.jaad.2018.12.040
      To the Editor: Female-to-male transgender patients (herein referred to as transgender men) receive masculinizing doses of testosterone to induce virilization and suppress menstruation. Studies have shown that elevated androgen levels among transgender men have been associated with an increased incidence of acne.
      • Ginsberg B.A.
      Dermatologic care of the transgender patient.
      • Katz K.A.
      • Furnish T.J.
      Dermatology-related epidemiologic and clinical concerns of men who have sex with men, women who have sex with women, and transgender individuals.
      • Wierckx K.
      • Van de Peer F.
      • Verhaeghe E.
      • et al.
      Short- and long-term clinical skin effects of testosterone treatment in trans men.
      • Nakamura A.
      • Watanabe M.
      • Sugimoto M.
      • et al.
      Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder.
      • Unger C.A.
      Hormone therapy for transgender patients.
      Studies suggest that testosterone therapy increases the development of acne, though severe acne occurs only rarely.
      • Wierckx K.
      • Van de Peer F.
      • Verhaeghe E.
      • et al.
      Short- and long-term clinical skin effects of testosterone treatment in trans men.
      Our study assessed the timing of acne onset relative to initiation of testosterone therapy in transgender men and the biologic, behavioral, and sociodemographic predictors of acne in this population.
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ginsberg B.A.
        Dermatologic care of the transgender patient.
        Int J Womens Dermatol. 2017; 3: 65-67
        • Katz K.A.
        • Furnish T.J.
        Dermatology-related epidemiologic and clinical concerns of men who have sex with men, women who have sex with women, and transgender individuals.
        Arch Dermatol. 2005; 141
        • Wierckx K.
        • Van de Peer F.
        • Verhaeghe E.
        • et al.
        Short- and long-term clinical skin effects of testosterone treatment in trans men.
        J Sex Med. 2014; 11: 222-229
        • Nakamura A.
        • Watanabe M.
        • Sugimoto M.
        • et al.
        Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder.
        Endocr J. 2013; 60: 275-281
        • Unger C.A.
        Hormone therapy for transgender patients.
        Transl Androl Urol. 2016; 5: 877-884